NEW YORK & MELBOURNE, Australia--(BUSINESS WIRE)--Anadis Ltd. (ANX.AX ; ANDIY.PK; CUSIP: 032517104) announced today that it has been informed by the Australian National Center in HIV Epidemiology and Clinical Research (NCHECR) and the University of New South Wales (UNSW), both in Sydney, that their Institutional Review Board has approved a major, phase IV multi-site randomized double-blind placebo controlled study of Anadis’ newest product, BioGard™. In the study, Anadis’ BioGard will be used alone and in combination with the new Merck (NYSE: MRK) anti-AIDS drug Isentress™ (raltegravir) This investigator initiated “CORAL” study is sponsored by NCHECR. BioGard is Anadis’ novel oral therapy contains high affinity anti-LPS antibodies and was recently approved for use by the Australian Therapeutic Goods Administration (TGA).
